-
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-03-14 Colton Ladbury, James Sanchez, Arnab Chowdhury, Joycelynne Palmer, An Liu, Anthony Stein, Myo Htut, Leonardo Farol, Ji-Lian Cai, George Somlo, Michael Rosenzweig, Jeffrey C Wong, Firoozeh Sahebi
We conducted a phase 1 study of a conditioning regimen with or without total marrow irradiation (TMI) before allogeneic hematopoietic stem cell transplantation for patients with high-risk or refractory multiple myeloma.
-
Advancements in Diagnosis and Multimodal Treatment Strategies for Retroperitoneal Tumors: A Comprehensive Review. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-03-13 Shuai Zhao, Longhe Sun, Jiajie Zhou, Ruiqi Li, Qiannan Sun, Wei Wang, Daorong Wang
Retroperitoneal tumors (RPTs) encompass both benign and malignant entities, constituting ~0.1% to 0.2% of all malignant tumors, of which 70% to 80% manifest malignancy. Predominantly, retroperitoneal sarcomas (RPS) represent the most prevalent subtype among RPT. With over 70 histologic forms identified, liposarcomas and leiomyosarcomas emerge as the primary constituents of RPS. Accurate diagnosis of
-
Flap Reconstruction Results in Longer Overall Treatment Time in Patients Treated with Surgery and Adjuvant Radiotherapy for Carcinoma of the Oral Cavity and Larynx. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-02-29 Nicolette R Drescher, Tayna Latortue, Ryan J Brisson, Vincent D Cassidy, Robert J Amdur, William M Mendenhall, Kathryn E Hitchcock
There is an inverse relationship between cancer cure and overall treatment time (OTT) in patients treated with surgical resection and radiotherapy (RT).
-
Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-02-20 Jianan Xu, Lin Tian, Wenlong Qi, Qingguo Lv, Tan Wang
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, particularly through the integration of genomic and epigenomic insights to enhance treatment outcomes for patients. We focus on the identification of key
-
Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-02-19 Ifeanyi O Ekpunobi, Shearwood McClelland
Spinal metastases are common in metastatic cancer, affecting around 40% of patients. The primary treatment involves radiation therapy, transitioning from conventional external beam radiation therapy (EBRT) to stereotactic body radiation therapy (SBRT) for its superior, durable response. While spine SBRT has gained popularity in the United States, Level I evidence supporting it over EBRT is limited
-
Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-02-12 Zakaria Chakrani, George Mellgard, Nathaniel Saffran, Stephen McCroskery, Nicole Taylor, Mann Patel, Bobby Liaw, Matthew Galsky, William K Oh, Che-Kai Tsao, Vaibhav G Patel
Androgen receptor-targeted therapies (ARTs) improve survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC); however, a significant portion of patients discontinue treatment for various reasons including treatment-related toxicity. We aim to describe reasons for ART treatment discontinuation and identify predictors associated with increased risk of treatment discontinuation
-
The Significance of the Redox Gene in the Prognosis and Therapeutic Response of Glioma. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-02-06 Huatao Niu, Honghua Cao, Xin Liu, Yanbei Chen, Zhaojin Cheng, Jinyong Long, Fuhua Li, Chaoyan Sun, Pin Zuo
Glioblastoma (GBM) is a fatal adult central nervous system tumor. Due to its high heterogeneity, the survival rate and prognosis of patients are poor. Thousands of people die of this disease every year all over the world. At present, the treatment of GBM is mainly through surgical resection and the combination of later drugs, radiotherapy, and chemotherapy. An abnormal redox system is involved in the
-
Feasibility, Tolerability, and Effectiveness of Transbronchial Interventions in Elderly Patients With Malignant Central Airway Obstruction: A Retrospective Single-institution Study. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-01-22 Kosuke Kashiwabara, Shinji Fujii, Shinsuke Tsumura, Ryuki Tokunaga
In elderly patients with malignant central airway obstruction (MCAO), the treating physicians often hesitate to undertake transbronchial interventions (TBIs) as a palliative procedure in view of the advanced age of the patients.
-
Disparities in the Receipt of Systemic Treatment in Metastatic Melanoma. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-01-22 Hanna Kakish, Omkar Pawar, Maira Bhatty, Susan Doh, Kathleen M Mulligan, Luke D Rothermel, Jeremy S Bordeaux, Ankit Mangla, Richard S Hoehn
In 2011, immunotherapy and targeted therapy revolutionized melanoma treatment. However, inequities in their use may limit the benefits seen by certain patients.
-
Effects of Adjuvant Chemotherapy on Early-onset Stage II Colon Cancer at Different Tumor Sites. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-01-22 Chang Tan, Qianqian Wang, Shukun Yao
Left-sided colon cancer (LSCC) and right-sided colon cancer (RSCC) have shown distinct clinical and prognostic features. We investigated the effect of adjuvant chemotherapy (ACT) on cause-specific survival (CSS) in patients with stage II LSCC and RSCC.
-
Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2024-01-09 Brian Chou, Jae Han Lee, Lonnie Saetern, Bhanu Prasad Venkatesulu, James S Welsh, Matthew M Harkenrider
This study aims to evaluate the efficacy and toxicity of radiotherapy (RT) to oligoprogressive metastatic non-small cell lung cancer (NSCLC).
-
ACR-ARS Practice Parameter for Radiation Oncology. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-28 Simon Lo, Samuel Chao, Eleanor Harris, Jonathan Knisely, Join Y Luh, Pranshu Mohindra, Tony S Quang, Jason Ye, William Small, Naomi R Schechter
This practice parameter was revised collaboratively by the American College of Radiology (ACR), and the American Radium Society. This practice parameter provides updated reference literature regarding radiation oncology practice and its key personnel.
-
ACR-ARS Practice Parameter for Communication: Radiation Oncology. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-25 Hina Saeed, Paul Wallner, James Bates, Anupama Chundury, Laura Freedman, Timur Mitin, Gary Walker, William Small, Naomi R Schechter
This practice parameter was revised collaboratively by the American College of Radiology (ACR), and the American Radium Society (ARS). Timely, accurate, and effective communications are critical to quality and safety in contemporary medical practices. Radiation oncology incorporates the science and technology of complex, integrated treatment delivery and the art of providing care to individual patients
-
Impact of Maximum Point Dose Within the Planning Target Volume on Local Control of Nonsmall Cell Lung Cancer Treated With Stereotactic Body Radiotherapy. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-25 Erica L Braschi, Christopher G Morris, Anamaria R Yeung, Alexandra N De Leo
No consensus exists on the maximum dose delivered to the planning target volume (PTV) in the delivery of stereotactic body radiotherapy (SBRT) for primary lung cancer. We investigated whether higher biologically effective doses (BED) within the PTV were associated with improved tumor control.
-
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-22 Paul E Wallner, Don C Yoo, Jeremy Calais, Freddy E Escorcia, Carina Mari Aparici, Jeff Michalski, Michael Morris, Zachary S Morris, Daniel Pryma, Bryan M Rabatic, Navesh Sharma, Neha Vapiwala, Munir V Ghesani, Rathan M Subramaniam, William Small, Naomi R Schechter
This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology, and the Society of Nuclear Medicine and Molecular Imaging. The document is intended to serve as a resource for appropriately trained and licensed physicians who perform therapeutic procedures
-
Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-22 Lizhi Ning, Yaobang Liu, Xuefang He, Rui Han, Yuanfang Xin, Jiuda Zhao, Xinlan Liu
More than half of patients with early-stage estrogen receptor-positive (ER+) breast cancer relapse after completing 5 years of adjuvant endocrine therapy, so it is important to determine which patients are candidates for extended endocrine therapy. The clinical treatment score after 5 years (CTS5) is a prognostic tool developed based on postmenopausal ER+ breast cancer to assess the risk of late distant
-
Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Review and Guidelines. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-22 Krishan R Jethwa, Ed Kim, Jordan Berlin, Christopher J Anker, Leila Tchelebi, Gerard Abood, Christopher L Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
For patients with locoregionally confined pancreatic ductal adenocarcinoma (PDAC), margin-negative surgical resection is the only known curative treatment; however, the majority of patients are not operable candidates at initial diagnosis. Among patients with resectable disease who undergo surgery alone, the 5-year survival remains poor. Adjuvant therapies, including systemic therapy or chemoradiation
-
Emerging Futuristic Targeted Therapeutics: A Comprising Study Towards a New Era for the Management of TNBC. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-19 Tanuma Mistry, Arijit Nath, Ranita Pal, Sushmita Ghosh, Sutapa Mahata, Pranab Kumar Sahoo, Sinjini Sarkar, Trisha Choudhury, Partha Nath, Neyaz Alam, Vilas D Nasare
Triple-negative breast cancer is characterized by high lethality attributed to factors such as chemoresistance, transcriptomic, and genomic heterogeneity, leading to a poor prognosis and limiting available targeted treatment options. While the identification of molecular targets remains pivotal for therapy involving chemo drugs, the current challenge lies in the poor response rates, low survival rates
-
Third-line Treatment for Metastatic Triple-negative Breast Cancer: A Systematic Review and Network Meta-analysis. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-15 Mingqiang Shi, Zhoujuan Li, Tianzhuo Wang, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao
Metastatic triple-negative breast cancer (mTNBC) is an invasive histologic subtype with a poor prognosis and rapid progression. Currently, there is no standard therapy for the third-line treatment of mTNBC. In this study, we conducted a network meta-analysis to compare regimens and determine treatment outcomes.
-
Long-Term Outcomes after Abdominal Radiation for Wilms Tumor: A 20-Year Experience. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-13 Brianna Conte, Colette Shen, Patrick Thompson, Ian Davis, Dana L Casey
As radiation therapy (RT) for Wilms tumor (WT) evolves with more conformal techniques, it is necessary to evaluate patterns of failure and toxicity. We sought to determine the rate of local failure (LF) after abdominal RT in WT, specifically focusing on those with contained rupture treated with whole abdominal and pelvic RT (WAPRT) vs flank RT. Secondary objectives were to determine overall survival
-
Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated Autoantibodies and Computed Tomography. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-04 Xiao Liu, Qing Shen, Yuchan Wen, Zhijiao Jiang, Zheng Ma, Pinqiang Zeng, Jian He, Yu Liao, Yong Huang, Jing Huang
Diagnosis of malignant pulmonary nodules can greatly reduce the occurrence of lung cancer death, and computed tomography (CT) is commonly used in diagnosis. In addition, tumor-associated autoantibodies (TAAbs) show high specificity and stability. We aim to establish a computable risk model of pulmonary nodules by combining CT with TAAb detection.
-
Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-04 Matthew Ledenko, Lydia Mercado, Tushar Patel
In randomized clinical trials in patients with hepatocellular cancer (HCC), combination therapy with atezolizumab and bevacizumab (Atezo-Bev) prolonged survival, and these treatments have become the standard first-line therapy for advanced HCC. However, clinical trials may not reflect real-life clinical practice due to treatment selection criteria. Thus, our aim was to understand predictors of HCC
-
Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-12-04 Erin N McAndrew, Jeffrey Graham, Brenden Dufault, Danielle N Desautels, Christina A Kim
Although metastatic breast cancer (MBC) is considered incurable, human epidermal growth receptor 2 (HER2)-directed therapy has improved outcomes significantly, with some patients experiencing durable responses to treatment. The aim of this study was to identify potential predictors of long-term survival (LTS) among patients with de novo HER2-positive MBC who received HER2-directed treatment.
-
Creatine Supplementation and Resistance Training in Patients With Breast Cancer (CaRTiC Study): Protocol for a Randomized Controlled Trial. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-11-29 Aitor Martinez Aguirre-Betolaza, Jon Cacicedo, Arkaitz Castañeda-Babarro
Creatine supplementation is an effective ergogenic nutrient for athletes, as well as for people starting a health or fitness program. Resistance training has previously been identified as an important method of increasing muscle mass and strength, especially in people with cancer to avoid sarcopenia. The potential of creatine supplementation for adaptations produced by resistance training in patients
-
Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-11-24 Christian M Alvarez, Maureen Aliru, Bhavani S Gannavarapu, Tidie Song, Linda Anne Gilmore, Santiago Olaechea, Daniel R Gomez, Chul Ahn, Rodney E Infante, Puneeth Iyengar
Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with non-small cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated
-
The Concerning Disaggregation of Gender and Racial/Ethnicity Disparity Investigation at Recent ASCO Annual Meetings. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-19 Ulysses G Gardner, Shearwood McClelland
There has been a recent emphasis in the peer-reviewed oncology literature on examining disparities by gender. Such emphasis provides an excellent opportunity to simultaneously examine race/ethnicity disparities in the same cohort. The degree to which gender disparities research has been performed concomitantly with racial disparities research at prominent oncologic societies has yet to be investigated
-
Second Hematologic Malignancies Associated With Primary Mediastinal Germ Cell Tumors: A Population-based Study. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-19 David Aguiar-Bujanda, Laura Croissier-Sánchez, Daniel Pérez-Cabrera, Saray Galván-Ruiz
Studies addressing second hematologic malignancies (SHMs) in patients with primary mediastinal germ cell tumors (PMGCTs) are scarce. To better describe this phenomenon, we analyzed a large case series from a population-based registry.
-
Survival Benefit of Primary Tumor Resection Combined With Chemotherapy in Patients With Unresectable Colorectal Mucinous Adenocarcinoma With Liver Metastasis. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-17 Shu-Wen Liao, Jie-Qun Zhan, Chu-Tian Liu, Hai-Tao Yu, Min-Jie Wen
To evaluate the survival benefit of combining primary tumor resection (PTR) and chemotherapy in patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM).
-
Characteristics Associated With Survival in Surgically Nonresected Pancreatic Adenocarcinoma in the Military Health System. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-17 Yvonne L Eaglehouse, Sarah Darmon, Michele M Gage, Craig D Shriver, Kangmin Zhu
Pancreatic cancer is often diagnosed at advanced stages with high-case fatality. Many tumors are not surgically resectable. We aimed to identify features associated with survival in patients with surgically nonresected pancreatic cancer in the Military Health System.
-
Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-12 James R Janopaul-Naylor, Andee Koo, David C Qian, Neal S McCall, Yuan Liu, Sagar A Patel
Artificial intelligence (AI) chatbots are a new, publicly available tool for patients to access health care-related information with unknown reliability related to cancer-related questions. This study assesses the quality of responses to common questions for patients with cancer.
-
Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors: A Systematic Review. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-12 Anjali Kulkarni, Carly Cooke, Rouhi Fazelzad, Michael Fung-Kee-Fung, Taymaa May, Tiffany Zigras
Low-grade serous ovarian cancer (LGSC) represents 5% of all epithelial ovarian cancers. They are characterized by indolent growth and KRAS and BRAF mutations, differing from high-grade serous ovarian cancer both clinically and molecularly. LGSC has low response rates to traditional systemic therapies, including chemotherapy and hormonal therapy. The objective of this systematic review was to appraise
-
Insurance Denial of Care for Randomized Controlled Trial-Eligible Patients: Incidence and Success Rate of Peer-To-Peer Authorization in Allowing Patients to Remain Trial-Eligible. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-10 Shearwood McClelland, Melissa Brately, Raed J Zuhour, Yilun Sun, Daniel E Spratt
Insurance denials for clinical trials serve as a pertinent barrier for patients to remain trial-eligible, thus hindering the development of therapies and the overall advancement of health care. We present results from an ongoing oncology randomized clinical trial regarding insurance denials and peer-to-peer authorization (P2PA) success rate in allowing patients to remain trial-eligible.
-
Impact of Coronavirus Disease-era Clinical Trial Reform on Cancer Trial Access in Rural/Underserved Regions of the Mid-West. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-09 Elizabeth A Gordon, Joshua W Gordon
The coronavirus disease 2019 pandemic refocused the cancer community on bringing clinical trials closer to patients and increasing access for traditionally underserved communities. Pandemic-era deregulation increased flexibility with telemedicine visits, less frequent testing, and the ability to have tests done locally. This study evaluates the impact of 2020 cancer clinical trial reform on trial accessibility
-
Surveillance With Serial Imaging and CA 19-9 Tumor Marker Testing After Resection of Pancreatic Cancer: A Single-Center Retrospective Study. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-10-09 Minerva Z Nong, Devanshi Dove, Dawn A Fischer, Kathryn C Hourdequin, Gregory H Ripple, Manik A Amin, Elizabeth B McGrath, Bassem I Zaki, Kerrington D Smith, Gabriel A Brooks
Most patients receiving curative-intent surgery for pancreatic cancer will experience cancer recurrence. However, evidence that postoperative surveillance testing improves survival or quality of life is lacking. We evaluated the use and characteristics of surveillance with serial imaging and CA 19-9 tumor marker testing at an NCI-designated comprehensive cancer center.
-
Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-09-26 Shaofu Yu, Shasha Zhai, Qian Gong, Chunhong Xiang, Jianping Gong, Lin Wu, Xingxiang Pu
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non-small cell lung cancer (NSCLC).
-
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-09-19 Bonny Chau, Elizabeth T Loggers, Lee D Cranmer, Harveshp Mogal, Jeremy M Sharib, Edward Y Kim, Stephanie K Schaub, Kelly G Paulson, Hannah M Linden, Jennifer M Specht, Janice N Kim, Sara H Javid, Michael J Wagner
Angiosarcoma is a rare complication of breast-conserving therapy. This study evaluated the change in incidence between 1992 and 2016 of secondary breast angiosarcoma (SBA) in patients with a history of breast cancer and the impact of management strategies for the original breast carcinoma on angiosarcoma treatment.
-
The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-09-13 Yusuf Acikgoz, Fatma Unal Yildirim, Selin Akturk Esen, Gokhan Ucar, Yakup Ergun, Oznur Bal, Mutlu Dogan, Dogan Uncu
We represent Sprouty 2 (Spry2) expression analysis and its association with key driver mutations and clinical features of patients with non-small cell lung cancer as the largest ex vivo data.
-
Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival: A Propensity Score-matched NCDB Analysis. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-09-08 James N Cantrell, Pawan Acharya, Sara K Vesely, Tyler C Gunter
Stereotactic body radiation therapy (SBRT) for early-stage non-small cell carcinoma of the lung (NSCLC) is increasingly utilized. We sought to assess overall survival (OS) for early-stage NSCLC patients receiving SBRT depending on staging method.
-
Recurrence Risk Stratification for Women With FIGO Stage I Uterine Endometrioid Carcinoma Who Underwent Surgical Lymph Node Evaluation. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-09-08 Ahmed I Ghanem, Aseem Bhatnagar, Muneer Elshaikh, Miriana Hijaz, Mohamed A Elshaikh
The aim of this study was to estimate the recurrence risk based on the number of prognostic factors for patients with stage I uterine endometrioid carcinoma (EC) who underwent surgical lymph node evaluation (SLNE) and were managed with observation.
-
Geographic Disparities in Access to Cancer Clinical Trials in Canada. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-08-29 Omar Abdel-Rahman
This study aims to evaluate geographic disparities in access to cancer clinical trials across Canada.
-
Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-08-25 Zhongxiu Zhu, Aixia Zhang
Non-small cell lung cancer (NSCLC) is a devastating but universal class of lung carcinoma with an unfavorable prognosis. This paper mainly investigated the correlation between lung immune prognostic index (LIPI) score and combined treatment of immune checkpoint inhibitor and chemotherapy (CHT) in patients with advanced NSCLC.
-
The Prognostic Significance of the Depth of Cervical Stromal Invasion in Women With FIGO Stage II Uterine Endometrioid Carcinoma. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-08-01 Sondos Al Khatib, Aseem Bhatnagar, Noor Elshaikh, Ahmed I Ghanem, Charlotte Burmeister, Ghassan Allo, Bassam Alkamachi, Alex Paridon, Mohamed A Elshaikh
The objective of this study was to investigate the prognostic significance of the depth of cervical stromal invasion (CSI) in women with FIGO stage II uterine endometrioid adenocarcinoma (EC).
-
Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-07-31 Ricardo García-Fumero, Cristina Fernández-López, Miguel Ángel Calleja-Hernández, Manuela Expósito-Ruiz, Jaime Espín Balbino, José Expósito-Hernández
To analyze the evolution of clinical outcomes derived from clinical trials on first-line therapies for advanced or metastatic non-small cell lung cancer (NSCLC) published between 2010 and 2020, focusing on how these outcomes impact survival rates and management of patients.
-
Treatment of Cancer Pain: A Systematic Review. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-07-24 Marcelen Rosenscheg, Julia Pedron, Lorena Pedroso
One of the biggest problems regarding the treatment of cancer patients is pain, whether due to the cancer or the treatment itself. Therefore, there is a search for treatments that aims to promote an effective treatment in this sense.
-
Assessing Geographic Variation in Rates of Cervical Cancer and Recurrent or Metastatic Cervical Cancer Among Medicaid Enrollees. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-07-17 Charles A Leath, Jessica Nysenbaum, Jie Ting, Yitong J Zhang, Anthony Fiori, Nathan Pauly
The objective of this study was to evaluate trends in prevalence of cervical cancer (CC) and rates of recurrent or metastatic cervical cancer (r/mCC) treatment initiation at the state and metropolitan statistical area (MSA) levels among Medicaid enrolled females from 2016 to 2019.
-
Comparison of Tumor Bed Delineation Using a Novel Radiopaque Filament Marker Versus Surgical Clips for Targeting Breast Cancer Radiotherapy. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-07-13 Utkarsh Shukla, Ulrich W Langner, David Linshaw, Sydney Tan, Kathryn E Huber, Chelsea J Miller, Esther Yu, Kara L Leonard, Mark Sueyoshi, Brett Diamond, David Edmonson, David E Wazer, Jennifer Gass, Jaroslaw T Hepel
Accuracy of tumor bed (TB) delineation is essential for targeting boost doses or partial breast irradiation. Multiple studies have shown high interobserver variability with standardly used surgical clip markers (CMs). We hypothesize that a radiopaque filament marker (FM) woven along the TB will improve TB delineation consistency.
-
Clinicopathologic Features of Noninvasive Inverted Urothelial Papillary Tumor. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-06-28 Ziyu Liu, Shumei Wei, Jinlong Tang
Clinicopathologic features and recurrence rates of inverted noninvasive urothelial papillary tumors have been poorly characterized to date with few larger studies evaluating long-term outcomes. The spectrum of histomorphology, clinical features, and prognosis of inverted lesions of the urinary bladder are retrospectively reviewed.
-
Prognostic Value of Pretreatment Serum Carcinoembryonic Antigen Level in 1130 Patients With Non-small Cell Lung Cancer: A Propensity Score Matching Cohort Study and Cumulative Mate-analysis. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-06-27 Fengzhou Li, Qing Lv, Shilei Zhao, Tao Guo, Gang Wang, Chundong Gu
Carcinoembryonic antigen (CEA) is the most frequently used tumor marker for non-small cell lung cancer (NSCLC). The current study aimed to provide the highest-level evidence of the prognostic value of pretreatment serum CEA level for NSCLC through the appropriate statistical methodology and large-sample cohorts.
-
Risk Factors for Recurrence and the Role of Radiotherapy in Low-grade Myofibroblastic Sarcoma: A Systematic Review. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-06-26 Garrett Mamikunian, Andrea Ziegler, Alec Block, Eric Thorpe
Low-grade myofibroblastic sarcoma (LGMS) is a rare malignancy that commonly occurs in the head and neck region. The role of radiotherapy has been unclear in treating LGMS and the risk factors for recurrence have remained undefined. The objective of this study is to determine risk factors for the recurrence of LGMS in the head and neck as well as the role of radiotherapy in the treatment of LGMS. A
-
PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-06-12 Andrea Giannini, Camilla Di Dio, Violante Di Donato, Ottavia D'oria, Maria Giovanna Salerno, Giuseppe Capalbo, Ilaria Cuccu, Giorgia Perniola, Ludovico Muzii, Giorgio Bogani
Ovarian cancer is the most lethal gynecologic malignancy, characterized by a high death-to-incidence ratio. Platinum-based chemotherapy is the mainstay of treatment for newly diagnosed and platinum-sensitive recurrent ovarian cancer. Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) have been incorporated into the treatment strategy for ovarian cancer. PARP inhibitors showed particular benefit
-
Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-06-05 Masafumi Yasunaga, Hideaki Yahata, Kaoru Okugawa, Emiko Hori, Kazuhisa Hachisuga, Shoji Maenohara, Keisuke Kodama, Hiroshi Yagi, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato
The aim of this study was to evaluate the progression-free survival (PFS) and overall response rate (ORR) of patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) retreated with platinum-containing chemotherapy (PCC) based on the platinum-free interval (PFI). We compared our results with those reported in the KEYNOTE-775 study (that used pembrolizumab plus lenvatinib)
-
Reduced Risk of Lymphedema With Intensity-modulated Radiation Therapy Compared With 3-dimensional Conformal Radiation Therapy in Patients With Cervical Cancer Who Received Postoperative Pelvic Radiation Therapy. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-26 Haruka Uezono, Kayoko Tsujino, Shuichiro Miyazaki, Mitsuru Marudai, Ryosuke Bessyo, Hatamei Takabayashi, Satoshi Yamaguchi, Yosuke Ota
To compare the long-term adverse events of intensity-modulated radiation therapy (IMRT) with those of 3-dimensional conformal radiation therapy (3D-CRT) in patients with intermediate-risk and high-risk uterine cervical cancer who underwent postoperative pelvic radiation therapy (PORT).
-
Cardiac Metastatic Tumors: Current Knowledge. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-26 Katarzyna Kopcik, Klaudia Kościelecka, Katarzyna Krzyżak
Cardiac tumors are a heterogeneous group of pathologic masses of the heart that contain primary tumors-benign or malignant, and secondary tumors. Metastases are significantly more frequent, mostly originating from lung, breast, gastrointestinal tract, or ovary carcinomas. Secondary cardiac tumors may be asymptomatic or may cause cardiovascular, systemic, or embolic symptoms. The study is a summary
-
Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-23 Antonio Pizuorno Machado, Malek Shatila, Isabella C Glitza Oliva, Mehmet Altan, Bilal Siddiqui, Yan Zhou, Krishnavathana Varatharajalu, Hao Chi Zhang, Anusha Thomas, Yinghong Wang
Immune checkpoint inhibitors (ICI) can cause immune-related adverse events (irAEs) such as colitis. irAEs can be managed by selective immunosuppressive therapy (SIT) agents such as infliximab and vedolizumab. We aimed to elucidate the incidence of subsequent new irAEs after exposure to SIT by describing patients' clinical course.
-
Prognostic Analysis of Lymphovascular Invasion in Stages I-III Colorectal Cancer: A Retrospective Study Based on Propensity Score Match. Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-23 Zhuoqun Lin, Yitao Zheng, Jun Yang, Wei Jin, Junqi Wang, Weichen Wang, Shaotang Li
Lymphovascular invasion (LVI) is a micropathological tumor factor believed to increase the risk of tumor metastasis and spread. Propensity score matching (PSM) is a statistical method that can control confounding factors. Current research rarely considers the confounding relationship between LVI and other factors that may influence prognosis. This study aimed to investigate the relationship between
-
Prognostic Value of Lymph Node Parameters in Elderly Patients With Stage III Serous Ovarian Cancer Based on Competing Risk Model Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-05 Xiangmei Sun, Yaru Peng, Jiaojiao Chen, Jiahao Lei, Weizong Liu, Zhengyi Li
Objectives: Competing risk models were used in this study. The purpose of this study was to assess the predictive usefulness of lymph node characteristics in elderly patients with stage III serous ovarian cancer. Methods: We conducted a retrospective analysis on 148,598 patients from 2010 to 2016 using the surveillance, epidemiology, and end results database. Lymph node characteristics were collected
-
Clinical Characteristics and Survival Analysis of Patients With Second Primary Malignancies After Hepatocellular Carcinoma Liver Transplantation: A SEER-based analysis Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-05 Qingbao Ding, Keyu Wang, Yupeng Li, Peng Peng, Dongyuan Zhang, Donglei Chang, Wentao Wang, Lei Ren, Fang Tang, Ziqiang Li
Background: Second primary malignancies (SPMs) after liver transplantation (LT) are becoming the leading causes of death in LT recipients. The purpose of this study was to explore prognostic factors for SPMs and to establish an overall survival nomogram. Methods: A retrospective analysis was conducted of data from the Surveillance, Epidemiology, and End Results (SEER) database on adult patients with
-
Association Between Statin Exposure and Incidence and Prognosis of Prostate Cancer: A Meta-analysis Based on Observational Studies Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-05-05 Zipei Cao, Jie Yao, Yujing He, Dandi Lou, Jianing Huang, Yeyuan Zhang, Meiling Chen, Zhizhen Zhou, Xiaomei Zhou
It is widely thought that statins have huge therapeutic potential against prostate cancer (PCA). This study aimed to investigate the effect of statin exposure on PCA incidence and prognosis. PubMed, Web of Science, Embase, and Cochrane databases were searched for observational studies on the association between statin exposure and PCA from inception until July 2022. The primary endpoints were the incidence
-
Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-04-28 John K. Chan, Jinan Liu, Jinlin Song, Cheryl Xiang, Eric Wu, Linda Kalilani, Jean A. Hurteau, Premal H. Thaker
Objective: This study used real-world population data to assess the trends of first-line (1L) poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance treatment uptake and outcomes in patients with primary advanced ovarian cancer (AOC). Methods: Patients diagnosed with AOC between January 1, 2017, and June 30, 2021, who completed 1L chemotherapy were selected from a real-world database. Descriptive
-
Prognostic Relevance of Negative Lymph Node Count in Resected Stage I–IIIa Small-cell Lung Cancer Am. J. Clin. Oncol. (IF 2.6) Pub Date : 2023-04-27 Hao Yang, Dongmei Li, Tong Liu
Objectives: The prognostic significance of the negative lymph node (NLN) count has been confirmed in various cancers but not in small-cell lung cancer (SCLC). We aimed to evaluate the correlation between the NLN count and the prognosis of patients with stages I–IIIa SCLC who underwent lobectomy. Methods: Data on the clinical characteristics of SCLC patients who underwent lobectomy between 2000 and